Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis

Ola Blixt, Deanna Bueti, Brian Burford, Diane Allen, Sylvain Julien, Michael A Hollingsworth, Alex Gammerman, Ian Fentiman, Joyce Taylor-Papadimitriou, Joy M. Burchell

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Introduction: Detection of serum biomarkers for early diagnosis of breast cancer remains an important goal. Changes in the structure of O-linked glycans occur in all breast cancers resulting in the expression of glycoproteins that are antigenically distinct. Indeed, the serum assay widely used for monitoring disease progression in breast cancer (CA15.3), detects a glycoprotein (MUC1), but elevated levels of the antigen cannot be detected in early stage patients. However, since the immune system acts to amplify the antigenic signal, antibodies can be detected in sera long before the antigen. We have exploited the change in O-glycosylation to measure autoantibody responses to cancer-associated glycoforms of MUC1 in sera from early stage breast cancer patients.Methods: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198). Five positive sera were selected for detailed definition of the reactive epitopes using on chip glycosylation technology and a panel of glycopeptides based on a single MUC1 tandem repeat carrying specific glycans at specific sites. Based on these results, larger amounts of an extended repertoire of defined MUC1 glycopeptides were synthesised, printed on microarrays, and screened with sera from a large cohort of breast cancer patients (n = 395), patients with benign breast disease (n = 108) and healthy controls (n = 99). All sera were collected in the 1970s and 1980s and complete clinical follow-up of breast cancer patients is available.Results: The presence and level of autoantibodies was significantly higher in the sera from cancer patients compared with the controls, and a highly significant correlation with age was observed. High levels of a subset of autoantibodies to the core3MUC1 (GlcNAcβ1-3GalNAc-MUC1) and STnMUC1 (NeuAcα2,6GalNAc-MUC1) glycoforms were significantly associated with reduced incidence and increased time to metastasis.Conclusions: Autoantibodies to specific cancer associated glycoforms of MUC1 are found more frequently and at higher levels in early stage breast cancer patients than in women with benign breast disease or healthy women. Association of strong antibody response with reduced rate and delay in metastases suggests that autoantibodies can affect disease progression.

Original languageEnglish (US)
Article numberR25
JournalBreast Cancer Research
Volume13
Issue number2
DOIs
StatePublished - Mar 8 2011

Fingerprint

Autoantibodies
Breast Neoplasms
Serum
Glycopeptides
Breast Diseases
Glycosylation
Polysaccharides
Disease Progression
Neoplasms
Glycoproteins
Neoplasm Metastasis
Antigens
Tandem Repeat Sequences
Early Detection of Cancer
Antibody Formation
Epitopes
Immune System
Biomarkers
Technology
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. / Blixt, Ola; Bueti, Deanna; Burford, Brian; Allen, Diane; Julien, Sylvain; Hollingsworth, Michael A; Gammerman, Alex; Fentiman, Ian; Taylor-Papadimitriou, Joyce; Burchell, Joy M.

In: Breast Cancer Research, Vol. 13, No. 2, R25, 08.03.2011.

Research output: Contribution to journalArticle

Blixt, O, Bueti, D, Burford, B, Allen, D, Julien, S, Hollingsworth, MA, Gammerman, A, Fentiman, I, Taylor-Papadimitriou, J & Burchell, JM 2011, 'Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis', Breast Cancer Research, vol. 13, no. 2, R25. https://doi.org/10.1186/bcr2841
Blixt, Ola ; Bueti, Deanna ; Burford, Brian ; Allen, Diane ; Julien, Sylvain ; Hollingsworth, Michael A ; Gammerman, Alex ; Fentiman, Ian ; Taylor-Papadimitriou, Joyce ; Burchell, Joy M. / Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. In: Breast Cancer Research. 2011 ; Vol. 13, No. 2.
@article{37b00780cafe4afe869dbc595acc4ae0,
title = "Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis",
abstract = "Introduction: Detection of serum biomarkers for early diagnosis of breast cancer remains an important goal. Changes in the structure of O-linked glycans occur in all breast cancers resulting in the expression of glycoproteins that are antigenically distinct. Indeed, the serum assay widely used for monitoring disease progression in breast cancer (CA15.3), detects a glycoprotein (MUC1), but elevated levels of the antigen cannot be detected in early stage patients. However, since the immune system acts to amplify the antigenic signal, antibodies can be detected in sera long before the antigen. We have exploited the change in O-glycosylation to measure autoantibody responses to cancer-associated glycoforms of MUC1 in sera from early stage breast cancer patients.Methods: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198). Five positive sera were selected for detailed definition of the reactive epitopes using on chip glycosylation technology and a panel of glycopeptides based on a single MUC1 tandem repeat carrying specific glycans at specific sites. Based on these results, larger amounts of an extended repertoire of defined MUC1 glycopeptides were synthesised, printed on microarrays, and screened with sera from a large cohort of breast cancer patients (n = 395), patients with benign breast disease (n = 108) and healthy controls (n = 99). All sera were collected in the 1970s and 1980s and complete clinical follow-up of breast cancer patients is available.Results: The presence and level of autoantibodies was significantly higher in the sera from cancer patients compared with the controls, and a highly significant correlation with age was observed. High levels of a subset of autoantibodies to the core3MUC1 (GlcNAcβ1-3GalNAc-MUC1) and STnMUC1 (NeuAcα2,6GalNAc-MUC1) glycoforms were significantly associated with reduced incidence and increased time to metastasis.Conclusions: Autoantibodies to specific cancer associated glycoforms of MUC1 are found more frequently and at higher levels in early stage breast cancer patients than in women with benign breast disease or healthy women. Association of strong antibody response with reduced rate and delay in metastases suggests that autoantibodies can affect disease progression.",
author = "Ola Blixt and Deanna Bueti and Brian Burford and Diane Allen and Sylvain Julien and Hollingsworth, {Michael A} and Alex Gammerman and Ian Fentiman and Joyce Taylor-Papadimitriou and Burchell, {Joy M.}",
year = "2011",
month = "3",
day = "8",
doi = "10.1186/bcr2841",
language = "English (US)",
volume = "13",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "2",

}

TY - JOUR

T1 - Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis

AU - Blixt, Ola

AU - Bueti, Deanna

AU - Burford, Brian

AU - Allen, Diane

AU - Julien, Sylvain

AU - Hollingsworth, Michael A

AU - Gammerman, Alex

AU - Fentiman, Ian

AU - Taylor-Papadimitriou, Joyce

AU - Burchell, Joy M.

PY - 2011/3/8

Y1 - 2011/3/8

N2 - Introduction: Detection of serum biomarkers for early diagnosis of breast cancer remains an important goal. Changes in the structure of O-linked glycans occur in all breast cancers resulting in the expression of glycoproteins that are antigenically distinct. Indeed, the serum assay widely used for monitoring disease progression in breast cancer (CA15.3), detects a glycoprotein (MUC1), but elevated levels of the antigen cannot be detected in early stage patients. However, since the immune system acts to amplify the antigenic signal, antibodies can be detected in sera long before the antigen. We have exploited the change in O-glycosylation to measure autoantibody responses to cancer-associated glycoforms of MUC1 in sera from early stage breast cancer patients.Methods: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198). Five positive sera were selected for detailed definition of the reactive epitopes using on chip glycosylation technology and a panel of glycopeptides based on a single MUC1 tandem repeat carrying specific glycans at specific sites. Based on these results, larger amounts of an extended repertoire of defined MUC1 glycopeptides were synthesised, printed on microarrays, and screened with sera from a large cohort of breast cancer patients (n = 395), patients with benign breast disease (n = 108) and healthy controls (n = 99). All sera were collected in the 1970s and 1980s and complete clinical follow-up of breast cancer patients is available.Results: The presence and level of autoantibodies was significantly higher in the sera from cancer patients compared with the controls, and a highly significant correlation with age was observed. High levels of a subset of autoantibodies to the core3MUC1 (GlcNAcβ1-3GalNAc-MUC1) and STnMUC1 (NeuAcα2,6GalNAc-MUC1) glycoforms were significantly associated with reduced incidence and increased time to metastasis.Conclusions: Autoantibodies to specific cancer associated glycoforms of MUC1 are found more frequently and at higher levels in early stage breast cancer patients than in women with benign breast disease or healthy women. Association of strong antibody response with reduced rate and delay in metastases suggests that autoantibodies can affect disease progression.

AB - Introduction: Detection of serum biomarkers for early diagnosis of breast cancer remains an important goal. Changes in the structure of O-linked glycans occur in all breast cancers resulting in the expression of glycoproteins that are antigenically distinct. Indeed, the serum assay widely used for monitoring disease progression in breast cancer (CA15.3), detects a glycoprotein (MUC1), but elevated levels of the antigen cannot be detected in early stage patients. However, since the immune system acts to amplify the antigenic signal, antibodies can be detected in sera long before the antigen. We have exploited the change in O-glycosylation to measure autoantibody responses to cancer-associated glycoforms of MUC1 in sera from early stage breast cancer patients.Methods: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198). Five positive sera were selected for detailed definition of the reactive epitopes using on chip glycosylation technology and a panel of glycopeptides based on a single MUC1 tandem repeat carrying specific glycans at specific sites. Based on these results, larger amounts of an extended repertoire of defined MUC1 glycopeptides were synthesised, printed on microarrays, and screened with sera from a large cohort of breast cancer patients (n = 395), patients with benign breast disease (n = 108) and healthy controls (n = 99). All sera were collected in the 1970s and 1980s and complete clinical follow-up of breast cancer patients is available.Results: The presence and level of autoantibodies was significantly higher in the sera from cancer patients compared with the controls, and a highly significant correlation with age was observed. High levels of a subset of autoantibodies to the core3MUC1 (GlcNAcβ1-3GalNAc-MUC1) and STnMUC1 (NeuAcα2,6GalNAc-MUC1) glycoforms were significantly associated with reduced incidence and increased time to metastasis.Conclusions: Autoantibodies to specific cancer associated glycoforms of MUC1 are found more frequently and at higher levels in early stage breast cancer patients than in women with benign breast disease or healthy women. Association of strong antibody response with reduced rate and delay in metastases suggests that autoantibodies can affect disease progression.

UR - http://www.scopus.com/inward/record.url?scp=84860390208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860390208&partnerID=8YFLogxK

U2 - 10.1186/bcr2841

DO - 10.1186/bcr2841

M3 - Article

VL - 13

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 2

M1 - R25

ER -